Somatropin pegylated - GeneScience Pharmaceuticals

Drug Profile

Somatropin pegylated - GeneScience Pharmaceuticals

Alternative Names: GenSci-004; Jintropin; Jintropin AQ; PEG-rhGH - GeneScience Pharmaceuticals; PEG-somatropin; Recombinant human growth hormone - GeneScience Pharmaceuticals

Latest Information Update: 24 Jul 2017

Price : $50

At a glance

  • Originator GeneScience Pharmaceuticals
  • Developer First Hospital of Jilin University; GeneScience Pharmaceuticals; Nanjing Medical University; Shanghai Jiao Tong University; Zhejiang University
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase II Short stature; Turner's syndrome

Most Recent Events

  • 31 Mar 2017 Phase-II clinical trials in Somatotropin deficiency (In adults) in China (SC) (NCT03104010)
  • 01 Mar 2016 Phase-II clinical trials in Turner's syndrome (In adolescents, In children) in China (SC) (NCT03189160)
  • 01 Oct 2014 Phase-II clinical trials in Short stature (In children) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top